NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company based in Los Angeles that develops treatments for cancers of the central nervous system, particularly malignant brain tumors such as glioblastoma.

Its lead programs are built around NEO100, a highly purified form of perillyl alcohol delivered intranasally, which is designed to reach the brain while bypassing the blood-brain barrier, and NEO212, an oral conjugate that links perillyl alcohol with the chemotherapy agent temozolomide. The company's technology originated from research at the University of Southern California and is protected by a portfolio of patents.

NeOnc is advancing these candidates through clinical trials and also studies their potential in other cancers that have spread to the brain.